CalciMedica Director Eric Roberts Buys 3,508 Shares at $2.79/Share.
ByAinvest
Monday, Aug 25, 2025 12:03 pm ET1min read
CALC--
This move by Hebbar comes after another notable investment by a key member of the company's leadership. On August 21, 2023, Chief Business Officer Eric W. Roberts purchased 3,508 shares of CalciMedica's common stock at a price of $2.79 per share [2]. This transaction underscores the confidence that CalciMedica's leadership has in the company's growth potential.
These investments by key executives suggest a positive outlook on the company's future performance. Such actions can influence investor sentiment and potentially drive demand for the company's stock. However, it is essential to note that while these purchases indicate confidence, they do not guarantee future performance or growth.
As always, investors should conduct their own research and consider their risk tolerance before making investment decisions. CalciMedica's recent filings and the actions of its leadership provide valuable insights into the company's current position, but they should be evaluated in the context of broader market conditions and the company's specific business environment.
References:
[1] https://www.tradingview.com/news/tradingview:8c934c0f3d904:0-calcimedica-s-chief-medical-officer-acquires-additional-shares/
[2] https://www.tradingview.com/news/tradingview:8c934c0f3d904:0-calcimedica-s-chief-medical-officer-acquires-additional-shares/
CalciMedica, Inc., a publicly traded company with the ticker symbol CALC, has announced that one of its directors and a 10% shareholder, Chief Business Officer Eric W. Roberts, has recently made a significant investment in the company's stock. Specifically, on August 21, 2023, Roberts purchased 3,508 shares of the company's common stock at a price of $2.79 per share. This transaction is a testament to the company's potential for growth and the confidence that its leadership has in its future prospects.
CalciMedica, Inc. (CALC), a publicly traded company, has seen its leadership demonstrate significant confidence in the company's future prospects. On August 19, 2025, Chief Medical Officer Sudarshan Hebbar acquired an additional 9,563 shares of the company's common stock, according to a recent SEC filing [1]. This purchase, totaling $26,961, was made at a weighted average price of $2.8194 per share. Following this transaction, Hebbar's direct ownership of CalciMedica's shares increased to 61,539.This move by Hebbar comes after another notable investment by a key member of the company's leadership. On August 21, 2023, Chief Business Officer Eric W. Roberts purchased 3,508 shares of CalciMedica's common stock at a price of $2.79 per share [2]. This transaction underscores the confidence that CalciMedica's leadership has in the company's growth potential.
These investments by key executives suggest a positive outlook on the company's future performance. Such actions can influence investor sentiment and potentially drive demand for the company's stock. However, it is essential to note that while these purchases indicate confidence, they do not guarantee future performance or growth.
As always, investors should conduct their own research and consider their risk tolerance before making investment decisions. CalciMedica's recent filings and the actions of its leadership provide valuable insights into the company's current position, but they should be evaluated in the context of broader market conditions and the company's specific business environment.
References:
[1] https://www.tradingview.com/news/tradingview:8c934c0f3d904:0-calcimedica-s-chief-medical-officer-acquires-additional-shares/
[2] https://www.tradingview.com/news/tradingview:8c934c0f3d904:0-calcimedica-s-chief-medical-officer-acquires-additional-shares/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet